Tedros Adhanom Ghebreyesus, Director-General of WHO, held a video conference at the organization’s headquarters in Geneva, Switzerland.
Ghebreyesus said that some countries are aware that Oxford University has suspended the use of the vaccine developed with the AstraZeneca company, and that investigations on this vaccine are ongoing.
Stating that more than 335 million Covid-19 vaccines have been applied worldwide, Ghebreyesus stated that no one died due to the vaccine, but at least 2.6 million people died due to the virus.
“More people will continue to die as vaccines are distributed as quickly and evenly as possible,” Ghebreyesus said. warned.
Sharing the information that Johnson and Johnson approved the Covid-19 vaccine for emergency use today, Ghebreyesus noted that this vaccine is the 4th vaccine approved by WHO.
Ghebreyesus stated that the vaccines they approved for emergency use will be used within the scope of the Covid-19 Vaccines Global Access Program (COVAX).
Stating that the COVAX initiative has ordered 500 million doses of vaccine to Johnson and Johnson, Ghebreyesus said that they will supply these vaccines as soon as possible.
22.1 BILLION DOLLAR FINANCING DEFICIT FOR WHO’S VACCINE PROGRAM
Ghebreyesus pointed out that they sent 29 million doses of vaccine to 38 countries under COVAX, 335 million doses of Covid-19 vaccine administered globally were made in 144 countries, 76 percent of them were administered in only 10 countries.
“The unfair distribution of vaccines remains the biggest threat to ending the pandemic and achieving a global recovery.” Ghebreyesus, who made the warning, said that countries made only $ 11 billion in pledges for the WHO’s global vaccine program “The ACT Accelerator” Program, including COVAX, and that there was a financing deficit of $ 22.1 billion.
Ghebreyesus called on countries to provide financial support for “The ACT Accelerator”.
WHO recommended on February 10 that the Covid-19 vaccine developed by Oxford-AstraZeneca be used in adults, including people over the age of 65.
The organization approved the emergency use of the Covid-19 vaccine produced by the Pfizer-BioNTech company on December 31.